Drug Trial Radar · NCT07708753
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Oct 1, 2029
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-resistant Primary Peritoneal Cancer
- Platinum-resistant Fallopian Tube Cancer
Interventions
SYS6043Drug
Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle.
Liposomal doxorubicin, paclitaxel, or topotecanDrug
Participants in the control group will receive investigator's choice chemotherapy: Liposomal doxorubicin 40 mg/m² every 28 days (Q4W), administered on Day 1 of each cycle; Paclitaxel 80 mg/m² every 28 days (Q4W), administered on Days 1, 8, 15, and 22 of each cycle; Topotecan 4 mg/m² every 28 days (Q4W), administered on Days 1, 8, and 15 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival by Blinded Independent Central Review (BICR) based on RECIST v1.1.Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 16 months.
- Overall SurvivalTime frame: From date of randomization to death due to any cause, up to approximately 39 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.